A polymorphic residue that attenuates the antiviral potential of interferon lambda 4 in hominid lineages

PLoS Pathogens

Volumn 14, Issue 10, 2018, Pages

  Bamford, Connor G G ^a   Aranday Cortes, Elihu ^a   Filipe, Ines Cordeiro ^a   Sukumar, Swathi ^a   Mair, Daniel ^a   Filipe, Ana da Silva ^a   Mendoza, Juan L ^b   Garcia, K Christopher ^b   Fan, Shaohua ^c   Tishkoff, Sarah A ^c   McLauchlan, John ^a  

^a MRC UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH   (United Kingdom)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; INTERFERON; INTERFERON LAMBDA 4; INTERLEUKIN 10; LIPOFECTAMINE; MONENSIN; NONSTRUCTURAL PROTEIN 5A; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; IFNL4 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

A-549 CELL LINE; ADAPTIVE IMMUNITY; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIVIRAL ACTIVITY; ARTICLE; CHIMPANZEE; CONTROLLED STUDY; CRISPR CAS SYSTEM; CYTOKINE PRODUCTION; CYTOPATHOGENIC EFFECT; DNA ISOLATION; DNA SEQUENCE; ENCEPHALOMYOCARDITIS VIRUS; FLOW CYTOMETRY; FRAMESHIFT MUTATION; GENE EXPRESSION ASSAY; GENETIC ANALYSIS; GENETIC TRANSFECTION; GENETIC VARIATION; GLYCOSYLATION; HEK293T CELL LINE; HEPARG CELL LINE; HEPATITIS C; HEPATITIS C VIRUS; HOMINID; HUMAN; HUMAN CELL; HUMAN TISSUE; ID50 (MEDIAN INFECTIOUS DOSE); IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; IN VITRO STUDY; INFLUENZA A VIRUS; LIVER BIOPSY; LUCIFERASE ASSAY; MDCK CELL LINE; NONHUMAN; OPEN READING FRAME; PROTEIN EXPRESSION LEVEL; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; SANGER SEQUENCING; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS; TRANSLATIONAL PROTEIN MODIFICATION; U2OS CELL LINE; UBIQUITINATION; VIRAL PLAQUE ASSAY; VIRUS REPLICATION; WESTERN BLOTTING; ZIKA VIRUS; ANIMAL; CARDIOVIRUS INFECTION; CELL CULTURE; DRUG EFFECT; EVOLUTION; GENE EXPRESSION REGULATION; GENETICS; HEPACIVIRUS; ISOLATION AND PURIFICATION; PAN TROGLODYTES; SPECIES DIFFERENCE; VIROLOGY; ZIKA FEVER;

ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL EVOLUTION; CARDIOVIRUS INFECTIONS; CELLS, CULTURED; ENCEPHALOMYOCARDITIS VIRUS; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERLEUKINS; PAN TROGLODYTES; POLYMORPHISM, SINGLE NUCLEOTIDE; SPECIES SPECIFICITY; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85054736511     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1007307     Document Type: Article

References (72)

1. Randall RE, Goodbourn S, Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol. 200889(1):1–47
2. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011472(7344):481–5. doi: 10.1038/nature09907 pmid: 21478870
3. Shaw AE, Hughes J, Gu Q, Behdenna A, Singer JB, Dennis T, et al. Fundamental properties of the mammalian innate immune system revealed by multispecies comparison of type I interferon responses. PLOS Biol. 201715(12):e2004086. doi: 10.1371/journal.pbio.2004086 pmid: 29253856
4. Schoggins JW, Interferon-stimulated genes: roles in viral pathogenesis. Curr Opin Virol. 20146C:40–6
5. Kotenko S V, Gallagher G, Baurin V V, Lewis-Antes A, Shen M, Shah NK, et al. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 20034(1):69–77. doi: 10.1038/ni875 pmid: 12483210
6. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 20034(1):63–8. doi: 10.1038/ni873 pmid: 12469119
7. Nice TJ, Baldridge MT, McCune BT, Norman JM, Lazear HM, Artyomov M, et al. Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity. Science. 2015347(6219):269–73. doi: 10.1126/science.1258100 pmid: 25431489
8. Galani IE, Triantafyllia V, Eleminiadou E-E, Koltsida O, Stavropoulos A, Manioudaki M, et al. Interferon-λ mediates non-redundant front-line antiviral protection against influenza virus infection without compromising host fitness. Immunity. 201746(5):875–90.e6. doi: 10.1016/j.immuni.2017.04.025 pmid: 28514692
9. Lazear HM, Daniels BP, Pinto AK, Huang AC, Vick SC, Doyle SE, et al. Interferon-λ restricts West Nile virus neuroinvasion by tightening the blood-brain barrier. Sci Transl Med. 20157(284):284ra59. doi: 10.1126/scitranslmed.aaa4304 pmid: 25904743
10. Odendall C, Dixit E, Stavru F, Bierne H, Franz KM, Durbin AF, et al. Diverse intracellular pathogens activate type III interferon expression from peroxisomes. Nat Immunol. 201415(8):717–26. doi: 10.1038/ni.2915 pmid: 24952503
11. Espinosa V, Dutta O, McElrath C, Du P, Chang Y-J, Cicciarelli B, et al. Type III interferon is a critical regulator of innate antifungal immunity. Sci Immunol. 20172(16):eaan5357. doi: 10.1126/sciimmunol.aan5357 pmid: 28986419
12. Marcello T, Grakoui A, Barba–Spaeth G, Machlin ES, Kotenko S V, Macdonald MR, et al. Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006131(6):1887–98. doi: 10.1053/j.gastro.2006.09.052 pmid: 17087946
13. Sommereyns C, Paul S, Staeheli P, Michiels T, IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 20084(3):e1000017. doi: 10.1371/journal.ppat.1000017 pmid: 18369468
14. Lazear HM, Nice TJ, Diamond MS, Interferon-λ: Immune functions at barrier surfaces and beyond. Immunity. 201543(1):15–28. doi: 10.1016/j.immuni.2015.07.001 pmid: 26200010
15. Manry J, Laval G, Patin E, Fornarino S, Itan Y, Fumagalli M, et al. Evolutionary genetic dissection of human interferons. J Exp Med. 2011. 208(13):2747–59. doi: 10.1084/jem.20111680 pmid: 22162829
16. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’hUigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009461(7265):798–801. doi: 10.1038/nature08463 pmid: 19759533
17. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna K V, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009461(7262):399–401. doi: 10.1038/nature08309 pmid: 19684573
18. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 201345(2):164–71. doi: 10.1038/ng.2521 pmid: 23291588
19. O’Brien TR, Pfeiffer RM, Paquin A, Lang Kuhs KA, Chen S, Bonkovsky HL, et al. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. J Hepatol. 201563(5):1103–10. doi: 10.1016/j.jhep.2015.06.035 pmid: 26186989
20. Key FM, Peter B, Dennis MY, Huerta-Sánchez E, Tang W, Prokunina-Olsson L, et al. Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4). PLoS Genet. 201410(10):e1004681. doi: 10.1371/journal.pgen.1004681 pmid: 25329461
21. Hong M, Schwerk J, Lim C, Kell A, Jarret A, Pangallo J, et al. Interferon lambda 4 expression is suppressed by the host during viral infection. J Exp Med. 2016213(12):2539–52. doi: 10.1084/jem.20160437 pmid: 27799623
22. Terczyńska-Dyla E, Bibert S, Duong FHT, Krol I, Jørgensen S, Collinet E, et al. Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nat Commun. 20145:5699. doi: 10.1038/ncomms6699 pmid: 25534433
23. Auton A, Abecasis GR, Altshuler DM, Durbin RM, Abecasis GR, Bentley DR, et al. A global reference for human genetic variation. Nature. 2015526(7571):68–74. doi: 10.1038/nature15393 pmid: 26432245
24. Hamming OJ, Terczyńska-Dyla E, Vieyres G, Dijkman R, Jørgensen SE, Akhtar H, et al. Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J. 201332(23):3055–65. doi: 10.1038/emboj.2013.232 pmid: 24169568
25. Luangsay S, Ait-Goughoulte M, Michelet M, Floriot O, Bonnin M, Gruffaz M, et al. Expression and functionality of Toll- and RIG-like receptors in HepaRG cells. J Hepatol. 201563(5):1077–85. doi: 10.1016/j.jhep.2015.06.022 pmid: 26144659
26. Mohamed M, McLees A, Elliott RM, Viruses in the Anopheles A, Anopheles B, and Tete serogroups in the Orthobunyavirus genus (family Bunyaviridae) do not encode an NSs protein. J Virol. 200983(15):7612–8. doi: 10.1128/JVI.02080-08 pmid: 19439468
27. Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R, Interferon-λ is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem. 2009284(31):20869–75. doi: 10.1074/jbc.M109.002923 pmid: 19457860
28. Lachance J, Vernot B, Elbers CC, Ferwerda B, Froment A, Bodo J-M, et al. Evolutionary history and adaptation from high-coverage whole-genome sequences of diverse African hunter-gatherers. Cell. 2012150(3):457–69. doi: 10.1016/j.cell.2012.07.009 pmid: 22840920
29. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016536(7616):285–91. doi: 10.1038/nature19057 pmid: 27535533
30. Mallick S, Li H, Lipson M, Mathieson I, Gymrek M, Racimo F, et al. The Simons Genome Diversity Project: 300 genomes from 142 diverse populations. Nature. 2016538(7624):201–6. doi: 10.1038/nature18964 pmid: 27654912
31. Paquin A, Onabajo OO, Tang W, Prokunina-Olsson L, Comparative functional analysis of 12 mammalian IFN-λ4 orthologs. J Interf Cytokine Res. 201636(1):30–6
32. Jones DM, Domingues P, Targett-Adams P, McLauchlan J, Comparison of U2OS and Huh-7 cells for identifying host factors that affect hepatitis C virus RNA replication. J Gen Virol. 201091(9):2238–48
33. Dill MT, Makowska Z, Duong FHT, Merkofer F, Filipowicz M, Baumert TF, et al. Interferon-γstimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. Gastroenterology. 2012143(3):777–86.e6. doi: 10.1053/j.gastro.2012.05.044 pmid: 22677194
34. Nanda S, Havert MB, Calderón GM, Thomson M, Jacobson C, Kastner D, et al. Hepatic transcriptome analysis of hepatitis C virus infection in chimpanzees defines unique gene expression patterns associated with viral clearance. PLoS One. 20083(10):e3442. doi: 10.1371/journal.pone.0003442 pmid: 18927617
35. Bigger CB, Brasky KM, Lanford RE, DNA Microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol. 200175(15):7059–66. doi: 10.1128/JVI.75.15.7059-7066.2001 pmid: 11435586
36. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci. 200299(24):15669–74. doi: 10.1073/pnas.202608199 pmid: 12441396
37. Yu C, Boon D, McDonald SL, Myers TG, Tomioka K, Nguyen H, et al. Pathogenesis of hepatitis E virus and hepatitis C virus in chimpanzees: similarities and differences. J Virol. 201084(21):11264–78. doi: 10.1128/JVI.01205-10 pmid: 20739520
38. Miknis ZJ, Magracheva E, Li W, Zdanov A, Kotenko S V, Wlodawer A. Crystal Structure of human interferon-λ1 in complex with its high-affinity receptor interferon-λR1. J Mol Biol. 2010404(4):650–64. doi: 10.1016/j.jmb.2010.09.068 pmid: 20934432
39. Mendoza JL, Schneider WM, Hoffmann H-H, Vercauteren K, Jude KM, Xiong A, et al. The IFN-λ-IFN-λR1-IL-10Rβ complex reveals structural features underlying type III IFN functional plasticity. Immunity201746(3):379–92. doi: 10.1016/j.immuni.2017.02.017 pmid: 28329704
40. Lu Y-F, Goldstein DB, Urban TJ, Bradrick SS, Interferon-λ4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden. Virology. 2015476:334–40. doi: 10.1016/j.virol.2014.12.020 pmid: 25577150
41. Dixon AS, Schwinn MK, Hall MP, Zimmerman K, Otto P, Lubben TH, et al. NanoLuc complementation reporter optimized for accurate measurement of protein interactions in cells. ACS Chem. Biol. 201611(2):400–8. doi: 10.1021/acschembio.5b00753 pmid: 26569370
42. Patterson N, Richter DJ, Gnerre S, Lander ES, Reich D, Genetic evidence for complex speciation of humans and chimpanzees. Nature. 2006441(7097):1103–8. doi: 10.1038/nature04789 pmid: 16710306
43. Green RE, Krause J, Briggs A. W, Maricic T, Stenzel U, Kircher M, et al. A Draft sequence of the neandertal genome. Science. 2010328(5979):710–22. doi: 10.1126/science.1188021 pmid: 20448178
44. Cohen TS, Prince AS, Bacterial pathogens activate a common inflammatory pathway through IFNλ regulation of PDCD4. PLoS Pathog. 20139(10):e1003682. doi: 10.1371/journal.ppat.1003682 pmid: 24098127
45. Mulangu S, Borchert M, Paweska J, Tshomba A, Afounde A, Kulidri A, et al. High prevalence of IgG antibodies to Ebola virus in the Efé pygmy population in the Watsa region, Democratic Republic of the Congo. BMC Infect Dis. 201616(1):263
46. Bukh J, A critical role for the chimpanzee model in the study of hepatitis C. Hepatology. 200439(6):1469–75. doi: 10.1002/hep.20268 pmid: 15185284
47. Bassett SE, Brasky KM, Lanford RE, Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles. J Virol. 199872(4):2589–99. pmid: 9525575
48. Walker CM, Comparative features of hepatitis C virus infection in humans and chimpanzees. Springer Semin Immunopathol. 199719(1):85–98. pmid: 9266633
49. Lanford RE, Guerra B, Bigger CB, Lee H, Chavez D, Brasky KM, Lack of response to exogenous interferon-α in the liver of chimpanzees chronically infected with hepatitis C virus. Hepatology. 200746(4):999–1008. doi: 10.1002/hep.21776 pmid: 17668868
50. Ray SC, Mao Q, Lanford RE, Bassett S, Laeyendecker O, Wang YM, et al. Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees. J Virol. 200074(7):3058–66. pmid: 10708420
51. Eslam M, Hashem AM, Leung R, Romero-Gomez M, Berg T, Dore GJ, et al. Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun. 20156:6422. doi: 10.1038/ncomms7422 pmid: 25740255
52. Ansari MA, Pedergnana V, L C Ip C, Magri A, Von Delft A, Bonsall D, et al. Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. Nat Genet. 201749(5):666–73. doi: 10.1038/ng.3835 pmid: 28394351
53. Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M, et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology. 2012142(4):978–88. doi: 10.1053/j.gastro.2011.12.055 pmid: 22248663
54. Park H, Serti E, Eke O, Muchmore B, Prokunina-Olsson L, Capone S, et al. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology. 201256(6):2060–70. doi: 10.1002/hep.25897 pmid: 22706965
55. Sheahan T, Imanaka N, Marukian S, Dorner M, Liu P, Ploss A, et al. Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe. 201415(2):190–202. doi: 10.1016/j.chom.2014.01.007 pmid: 24528865
56. Boldanova T, Suslov A, Heim MH, Necsulea A, Transcriptional response to hepatitis C virus infection and interferon‐alpha treatment in the human liver. EMBO Mol Med. 20179(6):816–34. doi: 10.15252/emmm.201607006 pmid: 28360091
57. Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci. 200299(24):15661–8. doi: 10.1073/pnas.202608299 pmid: 12441397
58. Foupouapouognigni Y, Sadeuh Mba SA, a Betsem EB, Rousset D, Froment A, Gessain A, et al. Hepatitis B and C virus infections in the three Pygmy groups in Cameroon. J Clin Microbiol. 201149(2):737–40. doi: 10.1128/JCM.01475-10 pmid: 21106785
59. Njouom R, Pasquier C, Ayouba A, Gessain A, Froment A, Mfoupouendoun J, et al. High rate of hepatitis C virus infection and predominance of genotype 4 among elderly inhabitants of a remote village of the rain forest of South Cameroon. J Med Virol. 200371(2):219–25. doi: 10.1002/jmv.10473 pmid: 12938196
60. Obajemu AA, Rao N, Dilley KA, Vargas JM, Sheikh F, Donnelly RP, et al. IFNλ4 attenuates antiviral responses by enhancing negative regulation of IFN signalling. J. Immunol. 2017199(11):3808–3820. doi: 10.4049/jimmunol.1700807 pmid: 29070670
61. Piehler J, Roisman LC, Schreiber G, New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface. J Biol Chem. 2000275(51):40425–33. doi: 10.1074/jbc.M006854200 pmid: 10984492
62. Piehler J, Thomas C, Garcia KC, Schreiber G, Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Immunol Rev. 2012250(1):317–34. doi: 10.1111/imr.12001 pmid: 23046138
63. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 20127(3):562–78. doi: 10.1038/nprot.2012.016 pmid: 22383036
64. Ran FA, Hsu PD, Wright J, Agarwala V, Scott D a, Zhang F, Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 20138(11):2281–308. doi: 10.1038/nprot.2013.143 pmid: 24157548
65. Donald CL, Brennan B, Cumberworth SL, Rezelj V V, Clark JJ, Cordeiro MT, et al. Full genome sequence and sfRNA interferon antagonist activity of Zika virus from Recife, Brazil. PLoS Negl Trop Dis. 201610(10):e0005048. doi: 10.1371/journal.pntd.0005048 pmid: 27706161
66. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci. 2006103(19):7408–13. doi: 10.1073/pnas.0504877103 pmid: 16651538
67. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science. 2005309(5734):623–6. doi: 10.1126/science.1114016 pmid: 15947137
68. Cowton VM, Angus AGN, Cole SJ, Markopoulou CK, Owsianka A, Dunlop JI, et al. Role of conserved E2 residue W420 in receptor binding and hepatitis C virus infection. J Virol. 201690(16):7456–68. doi: 10.1128/JVI.00685-16 pmid: 27279607
69. Domingues P, Bamford CGG, Boutell C, McLauchlan J, Inhibition of hepatitis C virus RNA replication by ISG15 does not require its conjugation to protein substrates by the HERC5 E3 ligase. J Gen Virol. 201596(11):3236–42. doi: 10.1099/jgv.0.000283 pmid: 26361997
70. Bigger C, Guerra B, Brasky K, Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol. 200478(24):13779–92. doi: 10.1128/JVI.78.24.13779-13792.2004 pmid: 15564486
71. Robinson MW, Aranday-Cortes E, Gatherer D, Swann R, Liefhebber JMP, Filipe ADS, et al. Viral genotype correlates with distinct liver gene transcription signatures in chronic hepatitis C virus infection. Liver Int. 201535(10):2256–64. doi: 10.1111/liv.12830 pmid: 25800823
72. Francioli LC, Menelaou A, Pulit SL, van Dijk F, Palamara PF, Elbers CC, et al. Whole-genome sequence variation, population structure and demographic history of the Dutch population. Nat Genet. 201446(8):818–25. doi: 10.1038/ng.3021 pmid: 24974849